Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07579845 · ClinicalTrials.gov registry record · NA
Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress
A NA study, sponsored by OvationLab.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT07579845: Recruiting NA study, sponsored by OvationLab.
NCT07579845 is a NA study that is actively recruiting participants, run by OvationLab. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07579845, a NA study, is actively recruiting participants, sponsored by OvationLab.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.
Primary Outcome
TruAge Test
Interventions
- DIETARY_SUPPLEMENT Humic and Fulvic Acid Dietary Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-05-05 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT07579845 shows while recruiting
NCT07579845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Humic and Fulvic Acid Dietary Supplement is the first listed.
NCT07579845 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07579845 about?
NCT07579845 is a clinical study titled "Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress". The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.
What is the current status of trial NCT07579845?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2026-05-05. Estimated completion is 2026-09.
What interventions are being tested in trial NCT07579845?
The interventions under investigation include: Humic and Fulvic Acid Dietary Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07579845?
This trial is sponsored by OvationLab, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07579845's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI